-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Increases By 502.6%
Short Interest in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Increases By 502.6%
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 22,900 shares, an increase of 502.6% from the August 15th total of 3,800 shares. Based on an average daily trading volume, of 21,200 shares, the short-interest ratio is presently 1.1 days. Approximately 0.1% of the shares of the stock are short sold.
Institutional Investors Weigh In On DA32 Life Science Tech Acquisition
Several institutional investors and hedge funds have recently added to or reduced their stakes in DALS. Saba Capital Management L.P. purchased a new stake in shares of DA32 Life Science Tech Acquisition during the 1st quarter worth approximately $10,883,000. Sculptor Capital LP boosted its stake in DA32 Life Science Tech Acquisition by 0.5% during the second quarter. Sculptor Capital LP now owns 767,528 shares of the company's stock worth $7,438,000 after acquiring an additional 3,900 shares in the last quarter. Citadel Advisors LLC lifted its stake in shares of DA32 Life Science Tech Acquisition by 21.0% in the second quarter. Citadel Advisors LLC now owns 720,941 shares of the company's stock worth $6,986,000 after buying an additional 125,000 shares in the last quarter. RP Investment Advisors LP lifted its position in DA32 Life Science Tech Acquisition by 653.1% during the first quarter. RP Investment Advisors LP now owns 408,856 shares of the company's stock valued at $3,972,000 after purchasing an additional 354,569 shares during the period. Finally, Arena Capital Advisors LLC CA increased its stake in shares of DA32 Life Science Tech Acquisition by 327.5% in the first quarter. Arena Capital Advisors LLC CA now owns 326,328 shares of the company's stock worth $3,170,000 after purchasing an additional 250,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.
Get DA32 Life Science Tech Acquisition alerts:DA32 Life Science Tech Acquisition Price Performance
Shares of NASDAQ:DALS remained flat at $9.74 during midday trading on Tuesday. The stock had a trading volume of 67 shares, compared to its average volume of 23,213. The business has a 50 day moving average of $9.72 and a two-hundred day moving average of $9.71. DA32 Life Science Tech Acquisition has a 1-year low of $9.58 and a 1-year high of $10.26.
DA32 Life Science Tech Acquisition Company Profile
(Get Rating)DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
Read More
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 22,900 shares, an increase of 502.6% from the August 15th total of 3,800 shares. Based on an average daily trading volume, of 21,200 shares, the short-interest ratio is presently 1.1 days. Approximately 0.1% of the shares of the stock are short sold.
DA32生命科学技术收购公司(纳斯达克:DALS-GET Rating)是空头股数8月份大幅增持的目标。截至8月31日,空头股数共有22,900股,比8月15日的3,800股增加了502.6%。以日均成交量二万一千二百股计算,目前短息比率为一点一天。大约0.1%的股票被卖空。
Institutional Investors Weigh In On DA32 Life Science Tech Acquisition
机构投资者参与收购DA32生命科学技术公司
Several institutional investors and hedge funds have recently added to or reduced their stakes in DALS. Saba Capital Management L.P. purchased a new stake in shares of DA32 Life Science Tech Acquisition during the 1st quarter worth approximately $10,883,000. Sculptor Capital LP boosted its stake in DA32 Life Science Tech Acquisition by 0.5% during the second quarter. Sculptor Capital LP now owns 767,528 shares of the company's stock worth $7,438,000 after acquiring an additional 3,900 shares in the last quarter. Citadel Advisors LLC lifted its stake in shares of DA32 Life Science Tech Acquisition by 21.0% in the second quarter. Citadel Advisors LLC now owns 720,941 shares of the company's stock worth $6,986,000 after buying an additional 125,000 shares in the last quarter. RP Investment Advisors LP lifted its position in DA32 Life Science Tech Acquisition by 653.1% during the first quarter. RP Investment Advisors LP now owns 408,856 shares of the company's stock valued at $3,972,000 after purchasing an additional 354,569 shares during the period. Finally, Arena Capital Advisors LLC CA increased its stake in shares of DA32 Life Science Tech Acquisition by 327.5% in the first quarter. Arena Capital Advisors LLC CA now owns 326,328 shares of the company's stock worth $3,170,000 after purchasing an additional 250,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.
几家机构投资者和对冲基金最近增持或减持了DALS的股份。萨巴资本管理公司在第一季度购买了DA32生命科学技术公司收购的新股份,价值约10,883,000美元。雕塑家Capital LP在第二季度将其在DA32生命科学技术公司收购中的股份增加了0.5%。雕塑家Capital LP现在拥有该公司767,528股股票,价值7,438,000美元,上个季度又收购了3,900股。Citadel Advisors LLC在第二季度将其在DA32 Life Science Tech收购的股份增加了21.0%。Citadel Advisors LLC现在持有该公司720,941股股票,价值6,98.6,000美元,上个季度又购买了125,000股。RP Investment Advisors LP在第一季度将其在DA32生命科学技术公司收购中的头寸提高了653.1%。RP Investment Advisors LP现在拥有408,856股该公司的股票,价值3972,000美元,在此期间又购买了354,569股。最后,Arena Capital Advisors LLC CA在第一季度增持了DA32生命科学技术收购的股份327.5%。Arena Capital Advisors LLC CA现在拥有该公司326,328股股票,价值3,170,000美元,上个季度又购买了250,000股。60.43%的股票目前由机构投资者持有。
DA32 Life Science Tech Acquisition Price Performance
DA32生命科学技术收购价格表现
Shares of NASDAQ:DALS remained flat at $9.74 during midday trading on Tuesday. The stock had a trading volume of 67 shares, compared to its average volume of 23,213. The business has a 50 day moving average of $9.72 and a two-hundred day moving average of $9.71. DA32 Life Science Tech Acquisition has a 1-year low of $9.58 and a 1-year high of $10.26.
周二午盘交易中,纳斯达克的股价持平于9.74美元。该股成交量为67股,而其平均成交量为23,213股。该业务的50日移动均线切入位在9.72美元,200日移动均线切入位在9.71美元。DA32生命科学技术收购的一年低点为9.58美元,一年高位为10.26美元。
DA32 Life Science Tech Acquisition Company Profile
DA32生命科学技术收购公司简介
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
DA32生命科学技术收购公司没有重大业务。它侧重于与一个或多个企业进行合并、资本换股、资产收购、股票购买、重组或相关业务合并。该公司打算确定生物技术和生命科学基础设施领域的业务合并目标。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- 免费获取StockNews.com关于DA32生命科学技术收购(DALS)的研究报告
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告,你需要知道的两件事
- 波动市场的三只价值股
- 3个能源类股接近突破杯形格局
- 这些股息获得者值得在你的投资组合中占有一席之地吗?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
获得DA32生命科学技术收购日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对DA32生命科学技术收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧